Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 7279818, 8 pages
https://doi.org/10.1155/2017/7279818
Review Article

Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?

1Clinic of Dermatology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia
2Clinic of Dermatology, Tartu University Hospital, 31 Raja St., 50417 Tartu, Estonia
3Institute of Biomedicine and Translational Medicine, Department of Biochemistry, The Centre of Excellence for Genomics and Translational Medicine, University of Tartu, 19 Ravila St., 50411 Tartu, Estonia

Correspondence should be addressed to Sirje Kaur; ee.mukiniilk@ruak.ejris

Received 18 May 2017; Revised 1 August 2017; Accepted 7 August 2017; Published 29 August 2017

Academic Editor: Anna Balato

Copyright © 2017 Sirje Kaur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Epidemiological studies suggest an increased prevalence of cardiovascular disease (CVD) in patients with psoriasis (PS). Therefore, emphasis has lately been laid on the necessity for clinical evaluation of the risk of CVD in these patients. The systemic inflammatory markers C-reactive protein (CRP) and interleukin- (IL-) 6, which have long been used to predict future CVD in the general population, are increased manyfold in patients with PS. Lipid abnormalities characterized by elevated triglycerides, low HDL cholesterol, and higher concentrations of LDL cholesterol and its oxidized form are also prevalent in patients. There is a need for additional laboratory markers for the assessment of cardiovascular status of patients with PS. Due to frequent comorbid overweight and obesity, biologically active compounds produced by adipocytes may have an impact on monitoring the status of the cardiovascular system of patients with PS. For this purpose, two adipokines, adiponectin and leptin, have been most extensively studied. The review focuses on some inflammatory and oxidative stress aspects in patients with PS through the analysis of the impact of prominent adipokines and oxidized low-density lipoprotein (oxLDL) to assess their eligibility for clinical practice as markers of CVD risk in patients with PS.